Screener
Avalo Therapeutics AVTX Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000049
FAQ
- What is Avalo Therapeutics's total equity?
- Avalo Therapeutics (AVTX) reported total equity of $448.66M in Q2 2026.
- How has Avalo Therapeutics's total equity changed year-over-year?
- Avalo Therapeutics's total equity increased by 329.0% year-over-year, from $104.57M to $448.66M.
- What is the long-term trend for Avalo Therapeutics's total equity?
- Over 5 years (2020 to 2025), Avalo Therapeutics's total equity has grown at a 27.6% compound annual growth rate (CAGR), from $24.56M to $83.05M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Avalo Therapeutics's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude